Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve …

In a mouse model of established arthritis, tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1 -dependent genes in joint tissue.

Tofacitinib binds predominantly to albumin and does not appear to bind to α1-acid glycoprotein. Tofacitinib distributes equally between red blood cells and plasma. Clearance mechanisms for …

Jul 3, 2025 · Tofacitinib is an oral Janus kinase (JAK) inhibitor, primarily targeting JAK1 and JAK3. It blocks intracellular signaling of multiple inflammatory cytokines and is approved for …

Feb 25, 2025 · Tofacitinib, a Janus kinase (JAK) inhibitor, has emerged as a primary therapeutic agent for managing autoimmune diseases such as rheumatoid arthritis,…

rent intra-cellular kinase pathways to modulate recruitment, activation and function of immune cells and other leukocytes. As our understanding of RA has advanced, intracellular signalling …

Oct 31, 2025 · 12.1 Mechanism of Action - Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor …

Jul 17, 2024 · Its mechanism of action involves disrupting the JAK-STAT signaling pathway, which is central to the activity of multiple cytokines. Despite its therapeutic benefits, caution is …

Mechanism of action Tofacitinib is a potent, selective inhibitor of the JAK family. In enzymatic assays, tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent TyK2. In contrast, …

Tofacitinib Citrate is a complex molecule that has made substantial contributions to modern medicine, particularly in the realm of autoimmune and inflammatory diseases. Its efficacy …